Raynaud’s Phenomenon (RP) is a multifactorial vasoconstrictive disease that is associated with recurrent and reversible ischemic crises of the extremities, in most cases, the fingers and toes. Its pathophysiology remains a complex issue involving neurovascular loss of regulation, endothelial dysfunction, increased sympathetic activity, and, in some instances, immune-mediated processes. Significant attention should be paid to the timely and proper identification, as Raynaud’s can be the primary diagnosis or the initial symptom of another underlying connective tissue disease. This review is a thorough evaluation of the clinical presentation, diagnostic modalities, and differential diagnosis to help identify and intervene on time. Present management treatment includes non-pharmacological methods, such as thermal protection, quitting smoking, and behavioral modification, as well as pharmacological treatment, including calcium channel blockers, Phosphodiesterase (PDE) inhibitors, prostacyclin analogues, and new targeted agents. Recent innovations and patent literature highlight progress in topical compositions, wearable thermotherapy apparatus, and drug-delivery systems that will help improve peripheral circulation and reduce vasospastic events. Potentially valuable approaches to refractory or severe cases include promising novel therapies, such as botulinum toxin injections, gene-based approaches, nitric-oxide modulating approaches, and rho-kinase inhibitors. Moreover, current changing knowledge about molecular pathways is fueling the quest to design precision-medicine interventions that are patient-specific. The review concludes by outlining future directions that emphasize early diagnosis, integrative therapeutic algorithms, advanced biomedical technologies, and innovation in patented treatment strategies to optimize long-term outcomes for individuals affected by RP.
Kumar et al. (Thu,) studied this question.